Exendin-4 decreases amphetamine-induced locomotor activity

Physiology and Behavior

Volumn 106, Issue 4, 2012, Pages 574-578

  Erreger, Kevin ^a,c,d   Davis, Adeola R ^a,c,d   Poe, Amanda M ^a,c,d   Greig, Nigel H ^e   Stanwood, Gregg D ^b,c,d   Galli, Aurelio ^a,c,d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c Center for Molecular Neuroscience   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Amphetamine; Dopamine; Exenatide; Glucagon like peptide 1; Psychostimulant

Indexed keywords

AMPHETAMINE; DOPAMINE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; AVERSION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG ABUSE; ENERGY METABOLISM; INGESTION; LOCOMOTION; MALE; MOBILIZATION; NONHUMAN; NUTRIENT; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

AMPHETAMINE; ANIMALS; ANTIMANIC AGENTS; ANXIETY; CENTRAL NERVOUS SYSTEM STIMULANTS; CONDITIONING, OPERANT; GLUCAGON-LIKE PEPTIDE 1; LITHIUM CHLORIDE; MALE; MOTOR ACTIVITY; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; VENOMS;

EID: 84860577661     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2012.03.014     Document Type: Article

References (66)

1. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87:1409-1439.
2. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
3. Holst J.J., Deacon C.F., Vilsboll T., Krarup T., Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med 2008, 14:161-168.
4. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992, 267:7402-7405.
5. Goke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J., et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993, 268:19650-19655.
6. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
7. Kastin A.J., Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003, 27:313-318.
8. Kastin A.J., Akerstrom V., Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002, 18:7-14.
9. Kanoski S.E., Fortin S.M., Arnold M., Grill H.J., Hayes M.R. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 2011, 152:3103-3112.
10. Alvarez E., Roncero I., Chowen J.A., Thorens B., Blazquez E. Expression of the glucagon-like peptide-1 receptor gene in rat brain. J Neurochem 1996, 66:920-927.
11. Merchenthaler I., Lane M., Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999, 403:261-280.
12. Jin S.L., Han V.K., Simmons J.G., Towle A.C., Lauder J.M., Lund P.K. Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 1988, 271:519-532.
13. Larsen P.J., Tang-Christensen M., Holst J.J., Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997, 77:257-270.
14. Llewellyn-Smith I.J., Reimann F., Gribble F.M., Trapp S. Preproglucagon neurons project widely to autonomic control areas in the mouse brain. Neuroscience 2011, 180:111-121.
15. Rinaman L. Ascending projections from the caudal visceral nucleus of the solitary tract to brain regions involved in food intake and energy expenditure. Brain Res. 2010, 1350:18-34.
16. Dossat A.M., Lilly N., Kay K., Williams D.L. Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. J Neurosci 2011, 31:14453-14457.
17. Alhadeff A.L., Rupprecht L.E., Hayes M.R. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 2012, 153:647-658.
18. De Silva A., Salem V., Long C.J., Makwana A., Newbould R.D., Rabiner E.A., et al. The gut hormones PYY(3-36) and GLP-1(7-36 amide) reduce food intake and modulate brain activity in appetite centers in humans. Cell Metab 2011, 14:700-706.
19. During M.J., Cao L., Zuzga D.S., Francis J.S., Fitzsimons H.L., Jiao X., et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003, 9:1173-1179.
20. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379:69-72.
21. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Baler R. Food and drug reward: overlapping circuits in human obesity and addiction. Curr Top Behav Neurosci in press, http://doi:10.1007/7854_2011_169.
22. Kenny P.J. Common cellular and molecular mechanisms in obesity and drug addiction. Nat Rev Neurosci 2011, 12:638-651.
23. Borgland S.L., Taha S.A., Sarti F., Fields H.L., Bonci A. Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 2006, 49:589-601.
24. Cummings D.E., Naleid A.M., Lattemann D.P.F. Ghrelin: a link between energy homeostasis and drug abuse?. Addict Biol 2007, 12:1-5.
25. Opland D.M., Leinninger G.M., Myers M.G. Modulation of the mesolimbic dopamine system by leptin. Brain Res 2010, 1350:65-70.
26. Knauf C., Cani P.D., Ait-Belgnaoui A., Benani A., Dray C., Cabou C., et al. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 2008, 149:4768-4777.
27. Mack C.M., Moore C.X., Jodka C.M., Bhavsar S., Wilson J.K., Hoyt J.A., et al. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006, 30:1332-1340.
28. Peters C.T., Choi Y.H., Brubaker P.L., Anderson G.H. A glucagon-like peptide-1 receptor agonist and an antagonist modify macronutrient selection by rats. J Nutr 2001, 131:2164-2170.
29. Young A.A., Gedulin B.R., Bhavsar S., Bodkin N., Jodka C., Hansen B., et al. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999, 48:1026-1034.
30. Williams J.M., Owens W.A., Turner G.H., Saunders C., Dipace C., Blakely R.D., et al. Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. PLoS Biol 2007, 5:e274.
31. Pijnenburg A.J., Honig W.M., Van Rossum J.M. Inhibition of d-amphetamine-induced locomotor activity by injection of haloperidol into the nucleus accumbens of the rat. Psychopharmacologia 1975, 41:87-95.
32. Shoblock J.R., Sullivan E.B., Maisonneuve I.M., Glick S.D. Neurochemical and behavioral differences between d-methamphetamine and d-amphetamine in rats. Psychopharmacology (Berl) 2003, 165:359-369.
33. Parkes D., Jodka C., Smith P., Nayak S., Rinehart L., Gingerich R., et al. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 2001, 53:260-267.
34. Meachum C.L., Bernstein I.L. Behavioral conditioned responses to contextual and odor stimuli paired with LiCl administration. Physiol Behav 1992, 52:895-899.
35. Parker L.A. Place conditioning in a three- or four-choice apparatus: role of stimulus novelty in drug-induced place conditioning. Behav Neurosci 1992, 106:294-306.
36. Tenk C.M., Kavaliers M., Ossenkopp K.P. Dose response effects of lithium chloride on conditioned place aversions and locomotor activity in rats. Eur J Pharmacol 2005, 515:117-127.
37. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998, 101:515-520.
38. Halford J.C., Wanninayake S.C., Blundell J.E. Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 1998, 61:159-168.
39. Kinzig K.P., D'Alessio D.A., Herman J.P., Sakai R.R., Vahl T.P., Figueiredo H.F., et al. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 2003, 23:6163-6170.
40. Seeley R.J., Blake K., Rushing P.A., Benoit S., Eng J., Woods S.C., et al. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 2000, 20:1616-1621.
41. Treit D., Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav 1988, 31:959-962.
42. Heusner C.L., Hnasko T.S., Szczypka M.S., Liu Y., During M.J., Palmiter R.D. Viral restoration of dopamine to the nucleus accumbens is sufficient to induce a locomotor response to amphetamine. Brain Res 2003, 980:266-274.
43. Chartoff E.H., Heusner C.L., Palmiter R.D. Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. Neuropsychopharmacology 2005, 30:1324-1333.
44. Rodriquez de Fonseca F., Navarro M., Alvarez E., Roncero I., Chowen J.A., Maestre O., et al. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 2000, 49:709-717.
45. Tachibana T., Tanaka S., Furuse M., Hasegawa S., Kato H., Sugahara K. Intracerebroventricular injection of glucagon-like peptide-1 decreases monoamine concentrations in the hypothalamus of chicks. Br Poult Sci 2002, 43:122-126.
46. Barrera J.G., Sandoval D.A., D'Alessio D.A., Seeley R.J. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 2011, 7:507-516.
47. Knauf C., Cani P.D., Perrin C., Iglesias M.A., Maury J.F., Bernard E., et al. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005, 115:3554-3563.
48. Yamamoto H., Lee C.E., Marcus J.N., Williams T.D., Overton J.M., Lopez M.E., et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002, 110:43-52.
49. Hayes M.R., Skibicka K.P., Grill H.J. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 2008, 149:4059-4068.
50. Gil-Lozano M., Perez-Tilve D., Alvarez-Crespo M., Martis A., Fernandez A.M., Catalina P.A., et al. GLP-1(7-36)-amide and Exendin-4 stimulate the HPA axis in rodents and humans. Endocrinology 2010, 151:2629-2640.
51. Tauchi M., Zhang R., D'Alessio D.A., Seeley R.J., Herman J.P. Role of central glucagon-like peptide-1 in hypothalamo-pituitary-adrenocortical facilitation following chronic stress. Exp Neurol 2008, 210:458-466.
52. Strawn J.R., D'Alessio D.A., Keck P.E., Seeley R.J. Failure of glucagon-like peptide-1 to induce panic attacks or anxiety in patients with panic disorder. J Psychiatr Res 2008, 42:787-789.
53. Grant P., Lipscomb D., Quin J. Psychological and quality of life changes in patients using GLP-1 analogues. J Diabetes Complications 2011, 25:244-246.
54. Tang-Christensen M., Cowley M.A. GLP-1 analogs: satiety without malaise?. Am J Physiol Regul Integr Comp Physiol 2007, 293:R981-R982.
55. McMahon L.R., Wellman P.J. PVN infusion of GLP-1-(7-36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am J Physiol 1998, 274:R23-R29.
56. Thiele T.E., Van Dijk G., Campfield L.A., Smith F.J., Burn P., Woods S.C., et al. Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am J Physiol 1997, 272:R726-R730.
57. Toft-Nielsen M.B., Madsbad S., Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999, 22:1137-1143.
58. Gutzwiller J.P., Drewe J., Goke B., Schmidt H., Rohrer B., Lareida J., et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999, 276:R1541-R1544.
59. Naslund E., Barkeling B., King N., Gutniak M., Blundell J.E., Holst J.J., et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999, 23:304-311.
60. Scott K.A., Moran T.H. The GLP-1 agonist exendin-4 reduces food intake in nonhuman primates through changes in meal size. Am J Physiol Regul Integr Comp Physiol 2007, 293:R983-R987.
61. Wise R.A. Dopamine, learning and motivation. Nat Rev Neurosci 2004, 5:483-494.
62. Wise R.A., Rompre P.P. Brain dopamine and reward. Annu Rev Psychol 1989, 40:191-225.
63. Wise R.A., Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol Rev 1987, 94:469-492.
64. Everitt B.J., Wolf M.E. Psychomotor stimulant addiction: a neural systems perspective. J Neurosci 2002, 22:3312-3320.
65. Raun K., von Voss P., Gotfredsen C.F., Golozoubova V., Rolin B., Knudsen L.B. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007, 56:8-15.
66. Kalivas P.W. Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate neuroplasticity. Dialogues Clin Neurosci 2007, 9:389-397.